FDA and FTC warned FluxxLab that its COVID-19 and CBDA/CBD tinctures are unapproved, misbranded drugs marketed with unsupported COVID-19 claims.
What happened
FDA reviewed https://fluxxlab.com/ on July 12, 2022, and FTC reviewed it on August 1, 2022. FDA says the website offered Covid-19 Immune Support Tincture and CBDA+CBD Oil Tincture for sale and made claims that they could prevent, treat, diagnose, or cure COVID-19. FDA cited these as unapproved new drugs and misbranded drugs; FTC said the health claims lacked competent and reliable scientific evidence.
What FDA found
FDA says the tinctures are unapproved new drugs because they are sold with claims to prevent, treat, diagnose, or cure COVID-19 without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)FDA says the products are misbranded drugs.
section 502 of the FD&C Act, 21 U.S.C. § 352FDA says introducing these products into interstate commerce is prohibited.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)FTC says the company advertised that the products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.
What FDA wants
FDA asks the company to immediately stop selling any unapproved or unauthorized products for COVID-19. Within 48 hours, the company must email COVID-19-Task-Force-CDER@fda.hhs.gov describing steps taken to correct the violations and prevent recurrence, with supporting documents; FTC separately requires certification within 48 hours that unsubstantiated claims have ceased.
Who should pay attention
- consumers who buy COVID-19-related supplements online
- online supplement and CBD brands making disease claims
- retailers or marketplaces that list tinctures with COVID-19 claims
This is a summary. Read the original letter on fda.gov.